Pervasis Therapeutics, Inc.

Abstract

In May 2005, Steve Bollinger was about to become president and chief operating officer of Pervasis Therapeutics, a small cell therapy start-up in Cambridge, Mass. If proven successful, Pervasis' product, Vascugel, could change the way vascular disease is treated and have a major impact in a large and underserved population. However, Vascugel had not yet gone into human clinical trials, and getting it to market would mean navigating the FDA approval process, as well as raising the capital necessary to finance the endeavor. It was up to Bollinger to decide on a strategy for Vascugel's clinical trials. In addition, he would have to decide how much money the company needed to raise, taking into account the interests of the company's founders and existing venture investors. Finally, while Bollinger was expected to lead the company for the next two to three years, Pervasis' board was planning to launch a search for a permanent CEO in the future.

More from the Author

Dr. Patrice Milos is the first CEO of Claritas Genomics (Claritas) and she faces a number of challenges in scaling the young company. Claritas was formed around a lab spun out from Boston Children's Hospital (BCH) which had performed genomic tests for the hospital. Now Milos has to generate new business for Claritas from pediatric hospitals around the country and provide a high level of timely service to its clients. The company also has a research mission to build a database of genomic information to improve the scientific understanding of various diseases.

Milos needs to find customers and strategic partners to reach the company's goals, but with whom should Claritas partner? A healthcare IT or software company? Healthcare technology and instruments companies? Other hospitals? What does the company need from its partners in order to reach scale? Was this the right time to bring in pure financial investors such as venture capital or private equity companies?

In January 2006, eClinicalWorks (eCW) had an acquisition opportunity that could fundamentally change the way they had done business since the inception of the company in 1999. eClinicalWorks was a privately run business in the healthcare information technology field that took in $25 million in revenue in 2005. Revenues for 2006 were projected to reach $40 million. This successful electronic medical record (EMR) company had grown thanks to their reliable software and responsive customer service. The company had achieved this growth without the help of any outside financing. The five co-founders of eCW, who treated each other like an extended family, invested years of sweat equity and hard work to shape eCW as they wanted. They were also proud of their company culture, which de-emphasized traditional company hierarchies and encouraged independent thinking and cooperative working arrangements across departments. Keeping the company private, in their view, had helped them to maintain this culture. The opportunity to acquire another EMR company offered eCW the chance to grow quickly in an industry that is estimated to take in more than $40 billion in overall revenues in 2007. But this acquisition would require outside financing of some sort. Was this the moment to accelerate the rate of growth to which eCW had become accustomed—catching up with, rather than anticipating, how their customer base would expand? Or should they maintain the same approach that had worked so well since 1999?

In mid-March 2007, Chris Kryder sat in his office and thought about how to best finance his company's growth. Over the previous five years as founder and CEO of D2Hawkeye, a Waltham, Massachusetts-based healthcare analytics company, Kryder had grown the firm from a six-person start-up into a leading developer and provider of medical analytics in the U.S. He had three term sheets in hand—two from strategic investors and one from a venture capital firm. Each offer had its advantages and disadvantages and Kryder needed to decide which offer to accept.